MedTrace Logo

Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

NCT00389935 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2011-08-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether Thalidomide is effective in the treatment of arteriovenous malformations in the gastrointestinal tract.

Conditions

  • Arteriovenous Malformation
  • Hereditary Hemorrhagic Telangiectasia
  • Hematochezia
  • Melena

Interventions

DRUG

Thalidomide

Thalidomide 50 - 200 mg once at nightime

Sponsors & Collaborators

  • Augusta University

    collaborator OTHER

  • University of Massachusetts, Worcester

    collaborator OTHER

  • Northport Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Atul Kumar, MD · Northport VAMC

  • James Gossage, MD · Augusta University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2011-06-30
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389935 on ClinicalTrials.gov